Jump to content

RAD52

From Wikipedia, the free encyclopedia

RAD52
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesRAD52, RAD52 homolog, DNA repair protein
External IDsOMIM: 600392; MGI: 101949; HomoloGene: 31118; GeneCards: RAD52; OMA:RAD52 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001166381
NM_001166382
NM_001166383
NM_011236

RefSeq (protein)

NP_001284348
NP_001284349
NP_001284350
NP_001284351
NP_602296

NP_001159853
NP_001159854
NP_001159855
NP_035366

Location (UCSC)Chr 12: 0.91 – 0.99 MbChr 6: 119.88 – 119.9 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

RAD52 homolog (S. cerevisiae), also known as RAD52, is a protein which in humans is encoded by the RAD52 gene.[5][6]

Function

[edit]

The protein encoded by this gene shares similarity with Saccharomyces cerevisiae Rad52, a protein important for DNA double-strand break repair and homologous recombination. This gene product was shown to bind single-stranded DNA ends, and mediate the DNA-DNA interaction necessary for the annealing of complementary DNA strands. It was also found to interact with DNA recombination protein RAD51, which suggested its role in RAD51-related DNA recombination and repair.[6]

Role in DNA recombination repair

[edit]

RAD52 mediates RAD51 function in homologous recombinational repair (HRR) in both yeast Saccharomyces cerevisiae and in mammalian cells of mice and humans. However, the RAD52 protein has distinctly different functions in HRR of yeast and humans. In S. cerevisiae, Rad52 protein, acting alone, facilitates the loading of Rad51 protein onto single-stranded DNA pre-coated with replication protein A in the presynaptic phase of recombination.[7][8]

In mice and humans, however, BRCA2 primarily mediates orderly assembly of RAD51 on ssDNA, the form that is active for homologous pairing and strand invasion.[9] BRCA2 also redirects RAD51 from dsDNA and prevents dissociation from ssDNA.[9] In addition, the four paralogs of RAD51, consisting of RAD51B (RAD51L1), RAD51C (RAD51L2), RAD51D (RAD51L3), XRCC2 form a complex called the BCDX2 complex. This complex participates in RAD51 recruitment or stabilization at damage sites.[10] The BCDX2 complex appears to act by facilitating the assembly or stability of the RAD51 nucleoprotein filament. However, in the presence of a BRCA2 mutation, human RAD52 can mediate RAD51 assembly on ssDNA and substitute for BRCA2 in homologous recombinational DNA repair,[11] though with lower efficiency than BRCA2.

In addition, human RAD52, in combination with ERCC1, promotes the error-prone homologous DNA repair pathway of single-strand annealing.[12] Though error prone, this repair pathway may be needed for survival of cells with DNA damage that is not otherwise repairable.

Human RAD52 also has an important role in repair of DNA double-strand breaks at active transcription sites during the G0/G1 phase of the cell cycle. Repair of these double-strand breaks appears to use an RNA template-based recombination mechanism dependent on RAD52.[13] The Cockayne Syndrome B protein (CSB) (coded for by ERCC6) localizes at double-strand breaks at sites of active transcription, followed by RAD51, RAD51C and RAD52 to carry out homologous recombinational repair using the newly synthesized RNA as a template.[13]

microRNAs and cancer risk

[edit]

Three prime untranslated regions (3'UTRs) of messenger RNAs (mRNAs) often contain regulatory sequences that can cause post-transcriptional RNA silencing. Such 3'-UTRs often contain binding sites for microRNAs (miRNAs). By binding to specific sites within the 3'-UTR, miRNAs can decrease gene expression of various mRNAs by either inhibiting translation or directly causing degradation of the transcript.

MicroRNAs (miRNAs) appear to regulate the expression of more than 60% of protein coding genes of the human genome.[14] One microRNA, miR-210, represses RAD52.[15] As noted by Devlin et al., miR-210 is up-regulated in most solid tumors and negatively affects the clinical outcome.[16]

The 3'-UTR of RAD52 also has a binding site for the microRNA let-7. Women with a single-nucleotide polymorphism (SNP) in the binding site for let-7 (rs7963551), that causes reduced binding of let-7, likely have increased expression of RAD52 (as was shown for this SNP in liver[17]). Women with this SNP in the 3'UTR of RAD52 showed a reduced breast cancer risk with an odds ratio of 0.84, 95% confidence interval of 0.75-0.95.[18]

In a Han Chinese population, the same SNP as above in the 3'-UTR of RAD52 binding site for let-7 (rs7963551) reduced the risk of glioma. The risk of glioma associated with the RAD52 rs7963551 genotype had an odds ratio (compared to those without the SNP) of 0.44 for those older than 41 years, and an odds ratio of 0.58 for those 41 years or younger.[19]

Li et al.[17] found significantly decreased hepatic cellular carcinoma risk among individuals with the RAD52 rs7963551 CC genotype (the same SNP as above) compared with those with the AA genotype in a Chinese population. They also found that in 44 normal human liver tissue samples, presence of the rs7963551 SNP was associated with a significant increase of RAD52 mRNA expression.

Thus increased RAD52 expression is protective against various cancers.

Another study of altered microRNA binding sites in RAD52 and their effects on cancer susceptibility was carried out by Naccarati et al.[20] They found two RAD52 microRNA binding sites that were frequently altered and had an effect on colon cancer risk. Individuals with a homozygous or heterozygous SNP in rs1051669 were at increased risk of colon cancer (OR 1.78, 95% CI 1.13–2.80, p = 0.01 for homozygotes and OR 1.72, 95% CI 1.10–2.692, p = 0.02 for heterozygotes). Heterozygous carriers of the other RAD52 SNP (rs11571475) were at decreased risk of colon cancer (OR 0.76, 95% CI 0.58–1.00, p = 0.05). Of 21 genes in the homologous recombinational repair pathway and 7 genes in the non-homologous end joining pathway examined, the only SNPs found in microRNA binding regions which were both at high enough frequency to evaluate and which affected risks of colon cancer, were the two in RAD52 and one in MRE11A.

DNA damage appears to be the primary underlying cause of cancer,[21] and deficiencies in DNA repair appear to underlie many forms of cancer.[22] If DNA repair is deficient, DNA damage tends to accumulate. Such excess DNA damage may increase mutational errors during DNA replication due to error-prone translesion synthesis. Excess DNA damage may also increase epigenetic alterations due to errors during DNA repair.[23][24] Such mutations and epigenetic alterations may give rise to cancer. The frequent microRNA-induced increase or deficiency of RAD52-mediated DNA repair due to microRNA binding alterations likely contributes to either the prevention or progression of breast, brain, liver or colon cancers.

Interactions

[edit]

RAD52 has been shown to interact with RAD51.[25] The Rad52 will ease the loading of Rad51 on ssDNA by interfering with the RPA protein.

Intragenic complementation

[edit]

When multiple copies of a polypeptide encoded by a gene form an aggregate, this protein structure is referred to as a multimer. When a multimer is formed from polypeptides produced by two different mutant alleles of a particular gene, the mixed multimer may exhibit greater functional activity than the unmixed multimers formed by each of the mutants alone. In such a case, the phenomenon is referred to as intragenic complementation. A Saccharomyces cerevisiae RAD52 mutant allele expressing a C-terminal truncated protein was found to complement other RAD52 mutant missense alleles.[26] This finding of intragenic complementation suggests that the RAD52 protein has a multimeric structure that allows cooperative interactions between the constituent monomers.

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000002016Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000030166Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Shen Z, Denison K, Lobb R, Gatewood JM, Chen DJ (Jan 1995). "The human and mouse homologs of the yeast RAD52 gene: cDNA cloning, sequence analysis, assignment to human chromosome 12p12.2-p13, and mRNA expression in mouse tissues". Genomics. 25 (1): 199–206. doi:10.1016/0888-7543(95)80126-7. PMID 7774919 – via Zenodo.
  6. ^ a b EntrezGene 5893 aka RAD52 homolog, DNA repair protein [''Homo sapiens'' (human)]
  7. ^ Shinohara A, Ogawa T (1998). "Stimulation by Rad52 of yeast Rad51-mediated recombination". Nature. 391 (6665): 404–7. Bibcode:1998Natur.391..404S. doi:10.1038/34943. PMID 9450759. S2CID 4304549.
  8. ^ New JH, Sugiyama T, Zaitseva E, Kowalczykowski SC (1998). "Rad52 protein stimulates DNA strand exchange by Rad51 and replication protein A". Nature. 391 (6665): 407–10. Bibcode:1998Natur.391..407N. doi:10.1038/34950. PMID 9450760. S2CID 4408959.
  9. ^ a b Holloman WK (2011). "Unraveling the mechanism of BRCA2 in homologous recombination". Nat. Struct. Mol. Biol. 18 (7): 748–54. doi:10.1038/nsmb.2096. PMC 3647347. PMID 21731065.
  10. ^ Chun J, Buechelmaier ES, Powell SN (2013). "Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway". Mol. Cell. Biol. 33 (2): 387–95. doi:10.1128/MCB.00465-12. PMC 3554112. PMID 23149936.
  11. ^ Feng Z, Scott SP, Bussen W, Sharma GG, Guo G, Pandita TK, Powell SN (2011). "Rad52 inactivation is synthetically lethal with BRCA2 deficiency". Proc. Natl. Acad. Sci. U.S.A. 108 (2): 686–91. doi:10.1073/pnas.1010959107. PMC 3021033. PMID 21148102.
  12. ^ Stark JM, Pierce AJ, Oh J, Pastink A, Jasin M (2004). "Genetic steps of mammalian homologous repair with distinct mutagenic consequences". Mol. Cell. Biol. 24 (21): 9305–16. doi:10.1128/MCB.24.21.9305-9316.2004. PMC 522275. PMID 15485900.
  13. ^ a b Wei L, Nakajima S, Böhm S, Bernstein KA, Shen Z, Tsang M, Levine AS, Lan L (2015). "DNA damage during the G0/G1 phase triggers RNA-templated, Cockayne syndrome B-dependent homologous recombination". Proc. Natl. Acad. Sci. U.S.A. 112 (27): E3495–504. Bibcode:2015PNAS..112E3495W. doi:10.1073/pnas.1507105112. PMC 4500203. PMID 26100862.
  14. ^ Friedman RC, Farh KK, Burge CB, Bartel DP (2009). "Most mammalian mRNAs are conserved targets of microRNAs". Genome Res. 19 (1): 92–105. doi:10.1101/gr.082701.108. PMC 2612969. PMID 18955434.
  15. ^ Crosby ME, Kulshreshtha R, Ivan M, Glazer PM (2009). "MicroRNA regulation of DNA repair gene expression in hypoxic stress". Cancer Res. 69 (3): 1221–9. doi:10.1158/0008-5472.CAN-08-2516. PMC 2997438. PMID 19141645.
  16. ^ Devlin C, Greco S, Martelli F, Ivan M (2011). "miR-210: More than a silent player in hypoxia". IUBMB Life. 63 (2): 94–100. doi:10.1002/iub.427. PMC 4497508. PMID 21360638.
  17. ^ a b Li Z, Guo Y, Zhou L, Ge Y, Wei L, Li L, Zhou C, Wei J, Yuan Q, Li J, Yang M (2015). "Association of a functional RAD52 genetic variant locating in a miRNA binding site with risk of HBV-related hepatocellular carcinoma". Mol. Carcinog. 54 (9): 853–8. doi:10.1002/mc.22156. PMID 24729511. S2CID 25174260.
  18. ^ Jiang Y, Qin Z, Hu Z, Guan X, Wang Y, He Y, Xue J, Liu X, Chen J, Dai J, Jin G, Ma H, Wang S, Shen H (2013). "Genetic variation in a hsa-let-7 binding site in RAD52 is associated with breast cancer susceptibility". Carcinogenesis. 34 (3): 689–93. doi:10.1093/carcin/bgs373. PMID 23188672.
  19. ^ Lu C, Chen YD, Han S, Wei J, Ge Y, Pan W, Jiang T, Qiu XG, Yang M (2014). "A RAD52 genetic variant located in a miRNA binding site is associated with glioma risk in Han Chinese". J. Neurooncol. 120 (1): 11–7. doi:10.1007/s11060-014-1527-x. PMID 25012956. S2CID 1082923.
  20. ^ Naccarati A, Rosa F, Vymetalkova V, Barone E, Jiraskova K, Di Gaetano C, Novotny J, Levy M, Vodickova L, Gemignani F, Buchler T, Landi S, Vodicka P, Pardini B (2015). "Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome". Oncotarget. 7 (17): 23156–69. doi:10.18632/oncotarget.6804. PMC 5029617. PMID 26735576.
  21. ^ Kastan MB (2008). "DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture". Mol. Cancer Res. 6 (4): 517–24. doi:10.1158/1541-7786.MCR-08-0020. PMID 18403632.
  22. ^ Harper JW, Elledge SJ (2007). "The DNA damage response: ten years after". Mol. Cell. 28 (5): 739–45. doi:10.1016/j.molcel.2007.11.015. PMID 18082599.
  23. ^ O'Hagan HM, Mohammad HP, Baylin SB (2008). "Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island". PLOS Genetics. 4 (8): e1000155. doi:10.1371/journal.pgen.1000155. PMC 2491723. PMID 18704159.
  24. ^ Cuozzo C, Porcellini A, Angrisano T, Morano A, Lee B, Di Pardo A, Messina S, Iuliano R, Fusco A, Santillo MR, Muller MT, Chiariotti L, Gottesman ME, Avvedimento EV (Jul 2007). "DNA damage, homology-directed repair, and DNA methylation". PLOS Genetics. 3 (7): e110. doi:10.1371/journal.pgen.0030110. PMC 1913100. PMID 17616978.
  25. ^ Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B, Cong F, Goff SP, Wu Y, Arlinghaus R, Baltimore D, Gasser PJ, Park MS, Sung P, Lee EY (Apr 1999). "Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl" (PDF). The Journal of Biological Chemistry. 274 (18): 12748–52. doi:10.1074/jbc.274.18.12748. PMID 10212258. S2CID 2587580.
  26. ^ Boundy-Mills KL, Livingston DM. A Saccharomyces cerevisiae RAD52 allele expressing a C-terminal truncation protein: activities and intragenic complementation of missense mutations. Genetics. 1993;133(1):39-49.

Further reading

[edit]